SavedAdd your journal

Journals / Türk Geriatri Dergisi / 2011 / Cilt: 14 - Sayı: 1

Possible elevation of transaminases with donepezil in a case with dementia of the alzheimer's type

Alzheimer tipi demanslı olguda olası donepezil kullanımına bağlı transaminaz yüksekliği

Fatih ÖZÇELİK
Erol ARSLAN
Selim NALBANT
İrfan YAVAŞOĞLU
Pages
82–84
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As transaminase levels may increase with use of donepezil in Alzheimer's disease, monitoring is crucial.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The use of donepezil is usually safe and well tolerated in Alzheimer's disease and hepatotoxicity is very rare.
📊
Key Findings & Data:A 79-year old female patient was diagnosed with Alzheimer's disease and prescribed donepezil 5 mg/day.
💡
Conclusion & Impact:As transaminase levels may increase with use of donepezil in Alzheimer's disease, monitoring is crucial.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The use of donepezil is usually safe and well tolerated in Alzheimer's disease and hepatotoxicity is very rare. A 79-year old female patient was diagnosed with Alzheimer's disease and prescribed donepezil 5 mg/day. Shortly after starting the therapy, her transaminase levels were found to be elevated. This hepatic enzyme elevation was thought to be due to donepezil use. As transaminase levels may increase with use of donepezil in Alzheimer's disease, monitoring is crucial.

Özet

Alzheimer Hastalığında donepezil kullanımı genel olarak güvenli ve iyi tolere edilir ve hepatotoksisite de çok nadirdir. Yetmiş dokuz yaşında kadın hastaya Alzheimer hastalığı tanısı konularak donepezil 5 mgr/gün dozunda verildi. Tedaviye başlandıktan bir süre sonra, hastada transaminaz seviyelerinde yükseklik saptandı. Karaciğerde meydana gelen bu enzim yüksekliği muhtemel donepezil kullanımına bağlı olduğu düşünüldü. Alzheimer hastalığında donepezil kullanımına bağlı transaminazlarda yükselme olabileceğinden takip önemlidir.

🔖

Cite This Article

ÖZÇELİK, F., ARSLAN, E., NALBANT, S., YAVAŞOĞLU, İ. (2022). Possible elevation of transaminases with donepezil in a case with dementia of the alzheimer's type. Türk Geriatri Dergisi, Cilt: 14 - Sayı: 1, 82–84. https://ajindex.com/articles/624037

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Bird TD, Miller BL. Dementia. In: Harrison’s Principles of Internal Medicine. 17th Ed. Fauci AS, Braunwald E, Kasper DL, et al. Eds. McGraw-Hill, New York, 2008:2536-49
  2. Hake AM. Use of cholinesterase inhibitors for treatment of Alzheimer disease. Cleveland Clinic Journal of Medicine 2001; 68: 608-16. 3. van Marum RJ. Update on the use of memantine in Alzheimer’s disease. Neuropsychiatr Dis Treat 2009; 5: 237-47
  3. Kumar S. Memantine: pharmacological properties and clinical uses. Neurol India 2004; 52: 307-9
  4. Rogers SL, Friedhoff LT. The ef?cacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7: 293–303
  5. Dierckx RI, Vandewoude MF. Donepezil-related toxic hepatitis. Acta Clin Belg 2008:63;339-42
  6. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994; 271: 992–8
  7. Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000; 57: 94–9. 9. ‹fleri PK, Efendi H. Alzheimer hastal›¤›’nda donepezil ve rivastigmin’in etkinli¤i ve güvenirli¤i. Turkish Journal of Geriatrics 2003; 6:119-23
  8. Tiseo PJ, Vargas R, Perdomo CA, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function. Br J Clin Pharmacol 1998; 46 (Suppl.1): 51–5
  9. Woodhouse K, Wynne HA. Age-related changes in hepatic function. Implications for drug therapy. Drugs Aging 1992; 2:243–55.